BioMérieux's Stock Rebounds by 2.4% After a 20% Drop Over a Week
BioMérieux's stock price has increased by 2.4% at the start of the week, reaching 72.65 euros during the session, after closing last Friday at 70.95 euros. This temporary rebound occurs in a context of significant deterioration of the stock, which has lost more than 20% over the past seven days and shows a decline of 37.1% over the year.
A Technical Rebound That Does Not Obscure the Extent of the Correction
The surge observed this Monday on BioMérieux occurs in a particularly degraded technical context. The price, at 72.65 euros, is significantly below the lower Bollinger band set at 77.18 euros, which is a classic signal of overselling. The RSI confirms this diagnosis: at 17, it is well below the usual oversold threshold of 30, which may explain the catch-up movement observed this morning.
The stock remains furthermore significantly distant from its moving averages. The MM50, at 92.33 euros, and the MM200, at 107.43 euros, illustrate the progressive decoupling of the price over several months. The support identified at 70.95 euros, precisely corresponding to last Friday's closing, has so far played its role as a floor. The nearest technical resistance is located at 95.05 euros, more than 30% above the current price. The CAC 40 is slightly up by 0.29% at 8,181.71 points, in a generally calm market environment in Europe.
A Standalone Stock in a Hesitant Healthcare Sector
BioMérieux's rebound contrasts with the trend observed in comparable healthcare sector stocks. In Europe, Sanofi is down by 0.40% and UCB by 0.42% during the session. Across the Atlantic, at the close of the day, Lilly (Eli) showed a marked decline of 3.67%, while Johnson & Johnson was down 1.37% and AbbVie fell by 1.11%. The sector dynamics thus do not seem to be a driving force for the Lyon-based in vitro diagnostics specialist.
The next key event for the group is the publication of its half-yearly results for 2026, scheduled for Tuesday, July 28, 2026. This milestone could provide tangible elements on the operational trajectory of the company, after a challenging stock market period. At this point, the nearly 30% loss over three months positions the stock at levels not seen in a long time, with no short-term catalyst identified to reverse the trend durably.
